3-(3,4-Dibromothiophen-2-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-(3,4-Dibromothiophen-2-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
• 化学式: C₁₂H₁₃Br₂NS
• 分子量: 363.11
• InChiKey: PUSULFRUMGICND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
  申请人：——

  公开号：US20020035122A1

  公开（公告）日：2002-03-21

  The present invention relates to novel 8-azabicyclo[3.2.1.]oct-2-ene and -octane derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of chemical substances.

  本发明涉及新颖的8-azabicyclo［3.2.1.］辛-2-烯和-辛烷衍生物，发现它们在尼古丁乙酰胆碱受体上是胆碱能配体。由于它们的药理特性，本发明的化合物可能有助于治疗与中枢神经系统（CNS）的胆碱能系统、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及由化学物质终止引起的戒断症状等多种疾病或紊乱。
• Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
  申请人：——

  公开号：US20040092508A1

  公开（公告）日：2004-05-13

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的制药组合物和用于本发明的化学物质。
• 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field
  申请人：NEUROSEARCH A/S

  公开号：US20040116703A1

  公开（公告）日：2004-06-17

  The present invention relates to novel 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的8-氮杂双环[3.2.1]辛-2-烯和-辛烷衍生物，这些衍生物被发现是乙酰胆碱受体的胆碱能配体。由于它们的药理特性，本发明的化合物可能对与中枢神经系统（CNS）的胆碱能系统相关的疾病或障碍，平滑肌收缩相关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症、疼痛以及因滥用化学物质而引起的戒断症状等多种疾病或障碍的治疗有用。
• TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE
  申请人：Olsen M. Gunnar

  公开号：US20070265241A1

  公开（公告）日：2007-11-15

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的药物组合物和用于本发明的化学物质。
• 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands
  申请人：NEUROSEARCH A/S

  公开号：EP1382605A2

  公开（公告）日：2004-01-21

  The present invention relates to novel 8-azabicyclo[3.2.1]oct-2-ene derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型 8-氮杂双环[3.2.1]辛-2-烯衍生物，发现它们是烟碱乙酰胆碱受体的胆碱能配体。 由于其药理特性，本发明化合物可用于治疗各种疾病或紊乱，如与中枢神经系统（CNS）胆碱能系统有关的疾病或紊乱、与平滑肌收缩有关的疾病或紊乱、内分泌疾病或紊乱、与神经变性有关的疾病或紊乱、与炎症有关的疾病或紊乱、疼痛以及终止滥用化学物质引起的戒断症状。